2024 Financial Guidance To participate in the conference call, interested parties must register in advance by clicking on this link. While it is not required, it is recommended you join 10 minutes prior to the event start. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique PIN that can be used to access the call. Forward-Looking Statements These and other important factors discussed under ...

During the first quarter of 2024, Medpace witnessed a robust revenue uptick year over year on the back of a strong backlog conversion rate. Its net new business awards were also strong during the period. We expect the company to have continued to register strong backlog addition in the second quarter. On its first-quarter earnings call in April, the company projected backlog conversion of approximately $1.56 billion to revenues in 12 months. This is likely to have reflected in the second-quarter result. Cen ...

The stock has a great record of positive earnings surprises, as it hasn't missed our earnings consensus estimate in any of the last four quarters. In its last earnings report on April 22, 2024, Medpace reported EPS of $3.2 versus consensus estimate of $2.45 while it missed the consensus revenue estimate by 0.33%. Medpace may be at a 52-week high right now, but what might the future hold for the stock? A key aspect of this question is taking a look at valuation metrics in order to determine if the company is ...

In the latest market close, Medpace (MEDP) reached $443, with a +1.84% movement compared to the previous day. The stock exceeded the S&P 500, which registered a gain of 0.55% for the day. Meanwhile, the Dow experienced a rise of 0.62%, and the technology-dominated Nasdaq saw an increase of 0.63%. Coming into today, shares of the provider of outsourced clinical development services had gained 10.38% in the past month. In that same time, the Medical sector gained 0.19%, while the S&P 500 gained 4.28%. Market ...

Core Viewpoint - Medpace (MEDP) has been upgraded to a Zacks Rank 1 (Strong Buy), indicating a positive outlook on its earnings estimates, which is a significant factor influencing stock prices [1][4]. Earnings Estimates and Stock Performance - The Zacks Rank system classifies stocks based on earnings estimates, with Zacks Rank 1 stocks historically generating an average annual return of +25% since 1988 [2]. - The correlation between changes in earnings estimates and stock price movements is strong, making the Zacks rating system valuable for investors [3][5]. Medpace's Earnings Outlook - For the fiscal year ending December 2024, Medpace is expected to earn $11.29 per share, reflecting a 27.1% increase from the previous year [8]. - Over the past three months, the Zacks Consensus Estimate for Medpace has risen by 7.2%, indicating a positive trend in earnings estimates [8]. Investment Implications - The upgrade to Zacks Rank 1 places Medpace in the top 5% of Zacks-covered stocks, suggesting potential for stock price appreciation in the near term [11]. - The Zacks rating system maintains a balanced approach, ensuring that only the top 20% of stocks are recognized for superior earnings estimate revisions, making them strong candidates for market-beating returns [9].

Have you been paying attention to shares of Medpace (MEDP) ? Shares have been on the move with the stock up 10% over the past month. The stock hit a new 52-week high of $424.49 in the previous session. Medpace has gained 38.4% since the start of the year compared to the 5.9% move for the Zacks Medical sector and the 5.4% return for the Zacks Medical Services industry. For the current fiscal year, Medpace is expected to post earnings of $11.28 per share on $2.17 billion in revenues. This represents a 27.14% ...

The most recent trading session ended with Medpace (MEDP) standing at $405.33, reflecting a -0.53% shift from the previouse trading day's closing. This move lagged the S&P 500's daily gain of 0.16%. Elsewhere, the Dow gained 0.04%, while the tech-heavy Nasdaq added 0.49%. The investment community will be closely monitoring the performance of Medpace in its forthcoming earnings report. The company is forecasted to report an EPS of $2.52, showcasing a 30.57% upward movement from the corresponding quarter of t ...

The investment community will be paying close attention to the earnings performance of Medpace in its upcoming release. The company is expected to report EPS of $2.52, up 30.57% from the prior-year quarter. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $529.73 million, up 14.94% from the year-ago period. Our research reveals that these estimate alterations are directly linked with the stock price performance in the near future. Investors can capitalize on this by using the Z ...

Investors will be eagerly watching for the performance of Medpace in its upcoming earnings disclosure. In that report, analysts expect Medpace to post earnings of $2.52 per share. This would mark year-over-year growth of 30.57%. Our most recent consensus estimate is calling for quarterly revenue of $529.73 million, up 14.94% from the year-ago period. The Zacks Rank system, which varies between #1 (Strong Buy) and #5 (Strong Sell), carries an impressive track record of exceeding expectations, confirmed by ex ...

Growth investors focus on stocks that are seeing above-average financial growth, as this feature helps these securities garner the market's attention and deliver solid returns. But finding a growth stock that can live up to its true potential can be a tough task. That's because, these stocks usually carry above-average risk and volatility. In fact, betting on a stock for which the growth story is actually over or nearing its end could lead to significant loss. However, it's pretty easy to find cutting-edge ...